Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Department of Oncology, Nanjing Drum Tower Hospital, Nanjing, People's Republic of China.
Int J Nanomedicine. 2023 May 2;18:2261-2273. doi: 10.2147/IJN.S408521. eCollection 2023.
PURPOSE: Recent studies have shown that traditional Chinese medicine (TCM), such as gambogic acid (GA), is involved in the regulation of tumor immune microenvironment and can be combined with other anti-tumor treatment strategies. Here, we used GA as an adjuvant to construct a nano-vaccine to improve the anti-tumor immune response of colorectal cancer (CRC). MATERIALS AND METHODS: We used a previously reported two-step emulsification method to obtain poly (lactic-co-glycolic acid) /GA nanoparticles (PLGA/GA NPs), and then CT26 colon cancer cell membrane (CCM) was used to obtain CCM-PLGA/GA NPs. This novel nano-vaccine, CCM-PLGA/GA NPs, was co-synthesized with GA as an adjuvant and neoantigen provided by CT26 CCM. We further confirmed the stability, tumor targeting, and cytotoxicity of CCM-PLGA/GA NPs. The regulatory effect on the tumor immune microenvironment, the anti-tumor efficacy, and the combined anti-tumor efficacy with anti-PD-1 monoclonal Antibodies (mAbs) of this novel nano-vaccine was also detected in vivo. RESULTS: We successfully constructed the CCM-PLGA/GA NPs. In vitro and in vivo tests showed low biological toxicity, as well as the high tumor-targeting ability of the CCM-PLGA/GA NPs. Besides, we revealed a remarkable effect of CCM-PLGA/GA NPs to activate the maturation of dendritic cells (DCs) and the formation of a positive anti-tumor immune microenvironment. CONCLUSION: This novel nano-vaccine constructed with GA as the adjuvant and CCM providing the tumor antigen can not only directly kill tumors by enhancing the ability of GA to target tumors, but also indirectly kill tumors by regulating tumor immune microenvironment, providing a new strategy for immunotherapy of CRC.
目的:最近的研究表明,传统中药(TCM),如藤黄酸(GA),参与肿瘤免疫微环境的调节,可以与其他抗肿瘤治疗策略相结合。在这里,我们使用 GA 作为佐剂构建纳米疫苗,以提高结直肠癌(CRC)的抗肿瘤免疫反应。
材料和方法:我们使用先前报道的两步乳化法获得聚(乳酸-共-羟基乙酸)/GA 纳米颗粒(PLGA/GA NPs),然后使用 CT26 结肠癌细胞膜(CCM)获得 CCM-PLGA/GA NPs。这种新型纳米疫苗,CCM-PLGA/GA NPs,与 GA 作为佐剂和 CT26 CCM 提供的新抗原共同合成。我们进一步证实了 CCM-PLGA/GA NPs 的稳定性、肿瘤靶向性和细胞毒性。还在体内检测了这种新型纳米疫苗对肿瘤免疫微环境的调节作用、抗肿瘤疗效以及与抗 PD-1 单克隆抗体(mAbs)的联合抗肿瘤疗效。
结果:我们成功构建了 CCM-PLGA/GA NPs。体外和体内试验表明,CCM-PLGA/GA NPs 具有低生物毒性和高肿瘤靶向能力。此外,我们揭示了 CCM-PLGA/GA NPs 激活树突状细胞(DCs)成熟和形成正向抗肿瘤免疫微环境的显著作用。
结论:这种新型纳米疫苗以 GA 为佐剂和 CCM 提供肿瘤抗原构建,不仅可以通过增强 GA 对肿瘤的靶向能力直接杀伤肿瘤,还可以通过调节肿瘤免疫微环境间接杀伤肿瘤,为 CRC 的免疫治疗提供了一种新策略。
Adv Drug Deliv Rev. 2011-6-6
Int J Nanomedicine. 2012-3-15
J Nanobiotechnology. 2025-5-17
J Nanobiotechnology. 2025-1-20
Exploration (Beijing). 2024-3-28
J Control Release. 2022-11
J Immunother Cancer. 2022-5
Adv Sci (Weinh). 2021-11
Int J Nanomedicine. 2021-3-11
Signal Transduct Target Ther. 2021-2-25